Diffuse large B cell lymphoma (DLBCL)

Diffuse large B-cell lymphoma (DLBCL) is usually treated by chemotherapy together with an antibody therapy called rituximab. However, this approach is not always successful - many people do not respond, or only have a partial response, so further 'salvage' treatment is needed. If salvage treatment is unsucessful, a stem cell transplant may be given, but sometimes the DLBCL returns after this. 

We are looking for new ways to treat people with DLBCL who have not responded to the standard treatment of chemotherapy and antibody therapy.

The TORCH trial is looking at a new drug called vistusertib for people with DLBCL that has continued to grow during standard treatment, or has come back afterwards.

We are also supporting the COBALT trial, which is using a CAR-T therapy in people who have DLBCL that has returned after a stem cell transplant. CAR-T therapy involves researchers genetically modifiying donor immune cells (T-cells) to seek out the DLBCL cancer cells in patients, and it's the first time this type of treatment has been used for people with DLBCL.



COBALT trial

Chief investigator - Dr Karl Peggs, University College London
High-grade non-Hodgkin lymphoma (HGNHL)
Evaluating CAR19 as an optimal bridge to allogeneic transplantation
For the first time in the UK, Professor Peggs is running a trial that will use CAR-T therapy to reduce the amount of DLBCL cells present, so people can be well enough to undergo a stem cell transplant. He will be using a CAR-T therapy, which works by modifying a patient's T-cells to recognise a protein called CD19 found on the surface of lymphoma cells. 

TORCH trial

Chief investigator - Dr Graham Collins, Oxford University Hospitals NHS Trust
Lymphoma Diffuse large B cell lymphoma (DLBCL)
A phase II study to determine the safety and efficacy of the dual mTORC inhibitor AZD2014 and to investigate additional toxicities in combination with rituximab in relapsed refractory DLBCL
This trial is looking at a new biological therapy called vistusertib for people with diffuse B cell lymphoma (DLBCL) that has continued to grow during standard treatment of chemotherapy and rituximab, or has come back afterwards.